NCT04929236View on ClinicalTrials.gov

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
DRUG

Panzyga

PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.

Trial Locations (6)

19104

RECRUITING

Octapharma Research Site, Philadelphia

22908

RECRUITING

Octapharma Research Site, Charlottesville

35233

RECRUITING

Octapharma Research Site, Birmingham

40202

RECRUITING

Octapharma Research Site, Louisville

77030

RECRUITING

Octapharma Research Site, Houston

92868

RECRUITING

Octapharma Research Site, Orange

Sponsors

Lead Sponsor

Octapharma
All Listed Sponsors
lead

Octapharma

INDUSTRY

NCT04929236 - Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients | Biotech Hunter | Biotech Hunter